AbbVie Inc. Long-Term Investments

Long-Term Investments of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-Term Investments growth rates and interactive chart. An accounting item that represents the company's investments, including stocks, bonds, real estate, and cash. Long-term investments are assets that a company intends to hold for more than a year. The long-term investment account differs largely from the short-term investment account in that short-term investments will most likely be sold, whereas the long-term investments will not be sold for years and, in some cases, may never be sold.


Highlights and Quick Summary

  • Long-Term Investments for the quarter ending September 29, 2021 was $340 Million (a 0.59% increase compared to previous quarter)
  • Year-over-year quarterly Long-Term Investments decreased by -19.81%
  • Annual Long-Term Investments for 2020 was $424 Million (a 241.94% increase from previous year)
  • Annual Long-Term Investments for 2019 was $124 Million (a -91.27% decrease from previous year)
  • Annual Long-Term Investments for 2018 was $1.42 Billion (a -32.06% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-Term Investments of AbbVie Inc.

Most recent Long-Term Investmentsof ABBV including historical data for past 10 years.

Interactive Chart of Long-Term Investments of AbbVie Inc.

AbbVie Inc. Long-Term Investments for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $340.0 $338.0 $379.0
2020 $424.0 $403.0 $225.0 $78.0 $424.0
2019 $93.0 $131.0 $1,473.0 $1,477.0 $124.0
2018 $1,420.0 $1,463.0 $1,505.0 $2,057.0 $1,420.0
2017 $2,090.0 $1,971.0 $2,052.0 $2,123.0 $2,090.0
2016 $1,783.0 $1,378.0 $1,400.0 $387.0 $1,783.0
2015 $145.0 $74.0 $134.0 $93.0 $145.0
2014 $92.0 $124.0 $130.0 $119.0 $92.0
2013 $118.0 $123.0 $121.0 $118.0 $118.0
2012 $119.0 $202.62 $237.0 $221.47 $119.0
2011 $229.0 $229.0
2010 $137.36 $137.36

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.